Uncategorized
LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics
SAN DIEGO & SHANGHAI & NEW YORK--(BUSINESS WIRE)--LENZ Therapeutics (LENZ), a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for presbyopia, today announced that it has entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia in Greater China. JIXING is a biotechnology company headquar